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No randomised trials have addressed the value of systematic aortic and pelvic lymphadenectomy (SL) in ovarian cancer
macroscopically confined to the pelvis. This study was conducted to investigate the role of SL compared with lymph nodes sampling
(CONTROL) in the management of early stage ovarian cancer. A total of 268 eligible patients with macroscopically intrapelvic
ovarian carcinoma were randomised to SL (N¼138) or CONTROL (N¼130). The primary objective was to compare the
proportion of patients with retroperitoneal nodal involvement between the two groups. Median operating time was longer and more
patients required blood transfusions in the SL arm than the CONTROL arm (240 vs 150min, Po0.001, and 36 vs 22%, P¼0.012,
respectively). More patients in the SL group had positive nodes at histologic examination than patients on CONTROL (9 vs 22%,
P¼0.007). Postoperative chemotherapy was delivered in 66% and 51% of patients with negative nodes on CONTROL and SL,
respectively (P¼0.03). At a median follow-up of 87.8 months, the adjusted risks for progression (hazard ratio [HR]¼0.72,
95%CI¼0.46–1.21, P¼0.16) and death (HR¼0.85, 95%CI¼0.49–1.47, P¼0.56) were lower, but not statistically significant, in the
SL than the CONTROL arm. Five-year progression-free survival was 71.3 and 78.3% (difference¼7.0%, 95% CI¼ –3.4–14.3%) and
5-year overall survival was 81.3 and 84.2% (difference¼2.9%, 95% CI¼ 7.0–9.2%) respectively for CONTROL and SL. SL detects
a higher proportion of patients with metastatic lymph nodes. This trial may have lacked power to exclude clinically important effects
of SL on progression free and overall survival.
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Epithelial ovarian cancer represents a significant health problem in
western countries, ranking fifth in cancer incidence and fourth in
site-specific causes of cancer deaths for females, with a life time
risk of about 2% (Parkin et al, 1988; Jemal et al, 2005). Ovarian
cancer is potentially curable by surgery; the cure rate is, however,
poor because in most patients the disease is diagnosed at an
advanced stage when overall five-year survival is only about 30%
(Jemal et al, 2005). Although there is currently no effective
screening strategy for ovarian cancer, proteomics and assessment
of CA-125 kinetics might make the diagnosis of early stage ovarian
cancer more frequent for the future (Liotta et al, 2001; Skates et al,
2003). While the surgical procedures and the requirements for
optimal intraperitoneal surgical staging of cancers apparently
confined to the pelvis (International Federation of Gynecologic
and Obstetrics (FIGO) stage I and II disease) (FIGO Committee on
Gynecologic Oncology, 2000) are well established, the surgical
approach to retroperitoneal nodes is controversial. Even when the
tumour is seemingly limited to the gonads or with pelvic extension
only the spread to retroperitoneal nodes is not uncommon.
Involvement of pelvic nodes have been reported to occur in 8–
15% (Piver et al, 1978; Burghadt et al, 1991) and of paraaortic
nodes in 5–24% of patients with stage I disease (Musumeci et al,
1977; Burghadt et al, 1991). Lymphatic spread in early ovarian
cancer is a predictor of outcome with potential clinical value
(Baiocchi et al, 1998; Di Re and Baiocchi, 2000). In fact, the
presence of node metastases upstages the patients to FIGO stage
IIIc disease and these patients are appropriate candidates for
adjuvant postoperative chemotherapic treatments. As prevalence
of lymph node metastases depends closely on the number of lymph
nodes removed and examined (Carnino et al, 1997) we have
designed a randomised trial to evaluate the role of systematic
lymphadenectomy at primary surgery in patients with ovarian
cancer macroscopically confined to the pelvis. Objectives of this
study were to provide insight into the biologic significance of node
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smetastases on clinical behavior and to assess the impact of
systematic lymphadenectomy on progression-free and overall
survival. Assessment of complications related to systematic
lymphadenectomy in this group of patients was also a main
objective of this study.
PATIENTS AND METHODS
Eligibility
Patients with histologically proven epithelial ovarian carcinoma,
macroscopically confined to the pelvis and optimally debulked
(residual tumour p1cm) were eligible for the study. Further
eligibility criteria included age o 75 years, Karnofsky performance
status X80 and no previous chemo or radiotherapy treatment. The
study protocol was revised and accepted by local ethical
committees; informed consent was obtained from all patients in
accordance with local and national legislation.
Type of surgery
Primary surgery was aimed at removing the primary tumour and
metastatic pelvic implants and included total abdominal hyster-
ectomy, bilateral salpingo-oophorectomy, total omentectomy,
appendectomy, random peritoneal biopsy specimens, peritoneal
washing and the removal of all macroscopic intra-pelvic tumour.
Control arm Patients enrolled in the control arm were supposed
to undergo random removal of pelvic and aortic nodes (sampling)
at the end of primary surgery.
Lymphadenectomy arm Primary surgery as detailed above was
followed by systematic pelvic and aortic lymphadenectomy.
Pelvic lymphadenectomy: The dissection begun at the origin of
the external iliac vessels and continued caudally around them
along the medial border of the psoas muscle; the lower limit of
external iliac lymphadenectomy was represented by the deep
inferior epigastric vessels. The lateral bounderies of dissection was
superficially delineated by the fascia covering the psoas muscle
and deeply by the fascia covering the internal obturator and
levator ani muscles, the medial margin of the lymphadenectomy,
was represented by an imaginary plane which is parallel to the
umbelical artery and is delineated by the ombelico-pubic fascia,
the bladder and the rectum.
In addition lymphatic tissue should be cleared from the
obturator fossa. The clearing of the obturator fossa begun with
the mobilizations of superficial obturator nodes which were
removed en bloc with the lymphatic fatty tissue which has been
previously separated from the internal iliac vessels to the origin of
the internal pudendal vessels. Unilateral lymphadenectomy was
allowed in unilateral tumours. Bilateral pelvic lymph node
dissection was deemed satisfactory when at least 20 nodes were
removed.
Aortic lymphadenectomy: Nodal dissection started at aortic
bifurcation by removing the superficial intercavoaortic, precaval
and preaortic nodal groups. Then, lymph nodes located lateral to
the cava (paracaval) were separated from the vena cava, the renal
capsule and the psoas muscle and removed en bloc. Afterward,
displacing the vena cava and the aorta laterally and medially, the
lymph nodes behind the cava (retrocaval nodal group) and the
lumbar vessels (deep intercavo-aortic nodes) were separated from
the prevertebral fascia and then removed. Removal of the most
cranial nodes, both behind and under the left renal vein was
performed after entering the right plane of dissection between the
Toldt’s and Gerota’s fasciae, mobilising the descending colon from
the renal capsule, the psoas, the ovarian pedicle and the ureter and
displacing it medially.
Aortic lymph node dissection was regarded as satisfactory when
at least 15 nodes were removed.
Surgical pathology
This protocol did not recommend specific methods for processing
lymph nodes but pathologists were asked to obtain two slides per
node.
First- and- second-line chemotherapy
After primary surgery and pathologic staging , patients with FIGO
stage IIb-c, IIIa and IIIc for nodal involment were to receive
platinum-based chemotherapy, regardless of the randomisation
arm. When the study was launched the role of post-operative
chemotherapy in stage I and IIa disease was controversial and the
use of chemotherapy rested on the discretion of the individual
investigator.
Statistical methods
In 1990 a comprehensive program to evaluate the impact of
lymphadenectomy in ovarian carcinoma was designed. Such
program aimed at evaluating staging accuracy in macroscopically
intrapelvic disease and survival in FIGO stage III disease (Bendetti
Panici et al, 2005). A third trial was launched to assess the
influence of lymphadenectomy performed at II look surgery after
primary chemotherapy on survival. In 1991 a network of Italian
hospitals coordinated at the Mario Negri Institute (Milan) started
randomisation of patients with macroscopically intrapelvic ovarian
cancer while in 1994 a second network of centres from Italy and
other four countries started accrual of advanced ovarian cancer
patients.
Randomisation with equal probability of assignment to each
treatment (no-lymphadenectomy vs systematic lymphadenectomy)
was carried out by a block arrangement balancing the treatment
assignment within centre. Randomisation was performed centrally
by telephone in six sites. To optimise intraoperative randomisation
procedures, one site, enrolling patients also for the trial on
advanced disease, randomised patients using a ‘blind envelope’
technique, that is , sealed envelopes that contained the treatment
assignment. Randomisation codes were generated at the Mario
Negri Institute, and the patient’s envelope (identified by a
registration number) was opened only after patient was enrolled.
Randomisation was carried out intraoperatively at the end of
endoperitoneal surgical procedures.
Pretreatment data and operative details were collected soon after
surgery. Chemotherapy and initial follow-up data were collected 6
months later and further follow-up data were collected annually
thereafter. All data were sent to the Coordinating Center at the
Mario Negri Institute.
The primary end point of this study was the prevalence of
patients with positive retroperitoneal nodes. Lymph node involve-
ment varies according to stage and depends closely on the number
of lymph nodes removed and examined. In series of stage I
patients undergoing lymph nodes sampling the prevalence ranged
from 2% (Tsuruchi et al, 1993) to 4,2% (Carnino et al, 1997) while
ranged from 13% (Di Re et al, 1989) to 24% (Burghadt et al, 1991)
in series of reported stage I patients undergoing pelvic alone or
pelvic and aortic lymphadenectomy. Therefore, the trial was
planned to recruit 280 patients to demonstrate a 10% difference in
the prevalence of lymph node positivity from 5% in nonlympha-
denectomy arm to 15% in lymphadenectomy arm with at least 80%
power (using a two-sided test and alpha of 5%). A target sample
size which was suitable to detect even a rather strong effect of
systematic lymphadenectomy on survival (e.g.: hazard ratio for
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from 80 to 86%) was deemed practically unattainable (521
patients).
Secondary endpoints were overall survival, which was defined as
the time interval between the date of randomisation and the date of
death from any cause, progression free survival (defined as the
time from randomisation to the earliest occurrence of progression
or death from any cause) and surgical morbidity.
The data from all eligible randomised patients were analyzed for
survival on an intention-to-treat basis, the survival curves were
estimated by the Kaplan–Meier method and compared by using
the log-rank test (Kaplan and Meier, 1958). We used the Kaplan–
Meier estimates of overall or progression-free survival in the
control group (no lymphadenectomy) at specific time points and
the hazard ratio to calculate absolute benefits at those time points
according to the formula: absolute benefit¼exp {HR*log[control
survival]}-control survival (Parmar and Machin, 1995). Although
this approach implicitly assumes proportional hazards, it is
preferable to comparing differences between Kaplan–Meier curves
at individual time points since is less susceptible to fluctuating
results. Additional analyses were done with the Cox proportional
hazards model while adjusting for multiple baseline character-
istics. When adjusting for the use of postoperative chemotherapy
we considered all the patients who had ad least one course of
chemotherapy and we modified the model to include postoperative
chemotherapy as a time-dependent covariate. The time t at which
the value of postoperative chemotherapy covariate switched from
no-chemotherapy to yes-chemotherapy was the date of the end of
therapy.
Comparisons of proportions between the two groups were done
by use of a two-sided w
2 test or a two-sided Fisher’s exact test if the
number of patients in a given category was five or fewer. The two-
sided Kruskal–Wallis (non-parametric) test was used to compare
the treatment effects of continuous variables that were expressed
as median with interquartile ranges.
RESULTS
Accrual
Between January 1991 and May 2003, 310 patients were enrolled
onto this study by seven participating centers. After pathology and
clinical review, 42 patients were deemed ineligible. Reasons for
ineligibility are detailed in Figure 1. Although there were three
times as many patients with other primary in the no-lymphade-
nectomy group than in the lymphadenectomy group (21 vs 7 cases,
respectively) we do not think this was a detection bias due to the
different surgery conducted.
Characteristics of patients
The characteristics of eligible patients are listed by randomised
arm in Table 1 and appear well balanced across the treatment
groups; of note, about 70% of patient population had FIGO stage I
at random and only nine out of the 72 patients with stage II disease
had residual tumour (p1cm).
Perioperative evaluation
In Table 2 we reported the median and 25th–75th percentiles of
resected nodes by treatment arm. Forty-four patients in the
lymphadenectomy arm were stage Ia and underwent ipsilateral
lymphadenectomy (median of resected nodes in this sub-
group¼36; pelvic 19, aortic 17).
As a consequence of the high number of resected nodes in the
lymphadenectomy arm, a higher proportion of these patients had
positive nodes at histologic examination than patients randomised
to control (overall: 22 vs 9%, P¼0.007; stage I at random: 18 vs
4%; stage II at random: 31 vs 20%). As expected, nodal
involvement was correlated with tumour grade (in the lymphade-
nectomy arm, 31% of patients with grade III tumour had
metastatic nodes vs 11% of patients with grade I/II tumour;
P¼0.004) and histological type of tumour (in the lymphadenect-
omy arm, 33% of patients with serous or undifferentiated tumour
had metastatic nodes vs 10% of patients with other cell types;
310 patients randomised 
158 allocated 
no lymphadenectomy lymphadenectomy
130 available
for intention-to-treat 
analysis
28 patients not eligible
Other primary = 21
Cervix = 4
Colon/rectum = 5
Endometrium = 9
Breast = 2
Tube = 1
Other histotype = 6
Cervix = 1
Colon/rectum = 3
Endometrium = 3
Other histotype = 7
Other FIGO stage = 1
14 patients not eligible
Other tumour = 7
152 allocated 
138 available
for intention-to-treat 
analysis
Figure 1 CONSORT trial flow diagram for patients with early stage
ovarian cancer who were accrued into the trial.
Table 1 Clinical and tumour characteristics by treatment arm
No
lymphadenectomy
(130 patients)
Lymphadenectomy
(138 patients)
n % n %
Median age (25th–75th
percentiles)
52 (44–59) 51 (43–60)
FIGO Stage (at random,
before pathologic staging)
I 90 69.2 102 73.9
II 39 30.0 33 23.9
Missing data 1 0.8 3 2.2
Residual tumour
None 126 96.9 133 96.4
p1cm 4 3.1 5 3.6
Tumour grade
1 20 15.4 30 21.7
2 41 31.5 29 21.0
3 65 50.0 72 52.2
Missing data 4 3.1 7 5.1
Cell type
Serous 43 33.1 61 44.2
Endometriod 34 26.2 24 17.4
Mucinous 22 16.9 14 10.1
Clear-cell 19 14.6 16 11.6
Undifferentiated 8 6.1 7 5.1
Other 2 1.5 8 5.8
Missing data 2 1.5 8 5.8
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lymphadenectomy arm, 21% had pelvic, 54% aortic and 25% pelvic
plus aortic involvement. Table 3 shows that systematic lympha-
denectomy had a significant impact on surgical parameters such as
median operative times, blood loss, and proportion of patients
undergoing blood transfusions. Median hospital stay for patients
undergoing systematic lymphadenectomy was one day longer than
patients undergoing no-lymphadenectomy (P¼0.003). Neither the
number of intraoperative nor perioperative/late complications was
statistically different between the two groups (eight cases vs four
and eight cases vs 16 in the control and lymphadenectomy arm,
respectively). Most of the difference in late morbidity was due to
formation of lymphocysts and lymphedema, which occurred in
eight cases in the lymphadenectomy group vs none in the control
arm. Adhesive small bowel obstruction occurred in one patient
after lymph nodes sampling only and in two patients after
lymphadenectomy. There were no surgery related deaths.
Post-operative adjuvant chemotherapies
Patients (61%) received adjuvant chemotherapy after surgery (66
and 56% for control and systematic lymphadenectomy, respec-
tively; P¼0.11). Patients (90%) with positive nodes and 56% of
patients with negative nodes received postoperative chemotherapy;
a statistically significant difference in the use of chemotherapy
emerged between groups in node negative patients (66 and 51% of
patients on control arm and systematic lymphadenectomy arm,
respectively, P¼0.03). No differences in chemotherapy schedules
emerged between groups. 97% of patients who received post-
operative chemotherapy underwent platinum based mono- (51%)
or multi- (46%) agent regimens while 3% patients received non
platinum-based chemotherapy regimens.
Progression-free and overall survival
At a median follow-up of 87.8 months (25th–75th percentiles: 62.7
to 120.6 months) tumour has recurred in 69 patients (25.7%) and
52 patients (19.4%) have so far died, six without evidence of
disease (2.2%). Recurrence was experienced by 30% of patients of
the control arm and by 22% of patients who underwent systematic
lymphadenectomy and the pattern of disease recurrences is shown
in Table 4. Figures 2 and 3 depict the overall and progression-free
survival, respectively, for all eligible patients.
Comparison of the Kaplan–Meier curves for progression free
survival gave a hazard ratio of 0.73 (95% CI¼0.46– 1.14; P¼0.17),
which translates into absolute increases in 3- and 5-year
progression-free survival of 6.2% (95% CI¼ 3.0 to 12.6%) and
7.0% (95% CI¼ 3.4 to 14.3%), respectively. Median progression-
free survival was not reached for patients in either arms.
Comparison of the Kaplan–Meier curves for overall survival
gave a hazard ratio of 0.83 (95% CI¼0.48–1.44), which translates
into absolute increases in 3- and 5-year overall survival of 1.8%
(95% CI¼ 4.6– 5.7%) and 2.9% (95% CI¼ 7.0–9.2%), respec-
tively. Median overall survival was still non reached in both
groups.
A Cox proportional hazards analysis was performed to adjust
the treatment comparison for baseline characteristics. When
histologic grade was taken into account the new hazard ratios
for death and progression remained virtually unchanged (Table 5).
Even when we took into account the unbalance in postoperative
chemotherapy use between treatment arms the hazard ratios for
death and progression were very similar (HR¼0.85, 95% CI¼0.49
to 1.48, P¼0.56 and HR¼0.72, 95% CI¼0.45 to 1.14, P¼0.16
respectively).
Finally we tried to evaluate the prognostic value of positive
aortic and/or pelvic lymph nodes inside each treatment group.
Metastatic nodal involvement was a strong negative prognostic
Table 2 Number of resected nodes by treatment arm
No lymph. (130 patients) Lymph. (138 patients)
Median no. (25th–75th percentiles) Median no. (25th–75th percentiles) P
Pelvic nodes 3.5 (0–8.5) 24 (15–33) o.0001
Aortic nodes 1 (0–4) 21 (15–30) o.0001
Pelvic and aortic nodes 5.5 (0–12) 47 (33–63) o.0001
Missing data 2 8
Table 3 Operative details and postoperative hospital stay
Surgical outcome No lymph. (130 patients) Lymph. (138 patients) P
Median operating time (min) (25th–75th percentiles) 150 (120–180) 240 (210–300) o.0001
Missing data 6 17
Median blood loss (ml) (25th–75th percentiles) 300 (200–550) 600 (400–900) o.0001
Missing data 9 18
Patients transfused (%) 21.85 35.5 0.012
Median hospital stay (days) (25th–75th percentiles) 6 (5–7) 7 (6–9) 0.003
Missing data 9 14
Table 4 Site of disease recurrence by treatment arm
No lymph. (130 patients) Lymph. (138 patients)
no. % no. %
No recurrence 91 70.0 108 78.0
Recurrence 39 30.0 30 22.0
Pelvic 13 9.2 11 8.0
Intraperitoneal 8 6.1 5 3.6
Retroperitoneal 4 3.1 2 1.4
Distant site 0 0 3 2.2
Multiple 13 10.0 9 6.5
Missing data 1 0.7 0 0
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while nodal involvement was no longer a determinant of survival
in the lymphadenectomy arm (HR¼0.71, CI¼0.24–2.06,
P¼0.52).
DISCUSSION
To our knowledge, this is the first randomised trial of patients with
ovarian carcinoma macroscopically confined to the pelvis that has
compared systematic lymphadenectomy and lymph nodes sam-
pling only. The main result of this study is that a statistically
significant higher proportion of patients was found to have
metastatic involvement of pelvic and/or aortic nodes in the
lymphadenectomy group than in the control group (22 vs 9%,
respectively, P¼0.007). That means an upstaging of these
apparent early stage ovarian cancers to a stage IIIc disease.
Although systematic lymphadenectomy was associated with an
improvement in progression-free and overall survival this
improvement was not statistically significant.
Systematic lympadenectomy is a major surgical major proce-
dure but this study provided evidence that it was feasible in the
framework of a pragmatic multicentre randomised trial. In the
lymphadenectomy arm the median number of removed pelvic and
aortic lymph nodes was 24 and 21, respectively. Overall, the
median number of removed nodes was 47 in the lymphadenectomy
arm and 5.5 in the control arm. The incidence of postoperative
complications was similar between the groups but the median
operating time in the lymphadenectomy arm was about 90min
longer and the blood loss about 300ml higher than in the control
arm, and 14% more patients underwent a blood transfusion in the
experimental group. The median postoperative hospital stay was
one day longer in the lymphadenectomy group than in the control
arm. Considering that endoperitoneal surgery for early ovarian
cancer is relatively simple the extra burden of the systematic
lymphadenectomy seems accetable in terms of operation length
and complications.
The prevalence of lymph node involvement depends closely on
the stage of the disease and the number of lymph nodes removed
and examined (Burghadt et al, 1991; Carnino et al, 1997). Our
study shows that when lymphadenectomy is systematically
performed, nearly a fourth of patients with ‘early-stage’ ovarian
cancer turns out to have retroperitoneal lymphatic spread. This is
still a conservative estimate of the true prevalence of nodal
involvement as only two sections were examined for each node and
therefore several micrometastastic deposits (0.2cm or smaller) and
also some macrometastases might have been missed. In early stage
ovarian cancer, positive nodes can be found in nine to 25% of
patients (Baiocchi et al, 1998). Such variabilility is due to the
relatively small size of patient series and the heterogeneity of
techiques used to detect and remove retroperitoneal nodes which
span from simple sampling (Chen and Lee, 1983; Lanza et al, 1988;
Carnino et al, 1997) to systematic lymphadenectomy (Di Re et al,
1989; Burghadt et al, 1991; Benedetti Panici et al, 1993; Carnino
et al, 1997; Baiocchi et al, 1998). Our findings are in keeping with
these data but represent the first direct comparison of the two
surgical approaches to retroperitoneal nodes and are not
hampered by the methodologic constrains of retrospective
analyses. Our study showed that, in the lymphadenectomy arm,
nodal status correlated with grading and histologic subtype.
Information about grading and histology are usually obtained
from biopsies well in advance of primary surgery so that clinicians
can optimise the lymphadenectomy diagnostic efficacy the
moment they plan it in patients with serous/undifferentiated or
grade 3 tumours.
Nodal metastases have been shown to independently correlate
with survival in epithealial ovarian cancer, both in advanced
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Figure 2 Overall survival (OS) for patients with optimally debulked early
ovarian carcinoma undergoing systematic aortic and pelvic lymphadenect-
omy (Lymphad.) vs lymph nodes sampling only (No lymphad). Five-year
overall survival was 81.6 and 84.0% (difference¼2.4%, 95% CI¼ 8.3 to
8.9%) respectively for lymph nodes sampling only and lymphadenectomy.
P
r
o
g
r
e
s
s
i
o
n
-
f
r
e
e
 
s
u
r
v
i
v
a
l
0.0
0.2
0.4
0.6
0.8
1.0
 2(log-rank): 1.9231 (P = 0.166)
Patients at risk
No lymphad.
No lymphad.
Lymphad.
Lymphad.
0
130
138 122 107 99 95 87 73
109 96 85 77 68 58
123456
Years from randomisation
Events Totals
41
34 138
130
Figure 3 Progression-free survival (PFS) for patients with optimally
debulked early ovarian carcinoma undergoing systematic aortic and pelvic
lymphadenectomy (Lymphad.) vs lymph nodes sampling only (No
lymphad.). Five-year progression-free survival was 73.4 and 78.3%
(difference¼4.9%, 95% CI¼ 5.9 to 12.5%) respectively, for lymph nodes
sampling only and lymphadenectomy.
Table 5 Multivariable cox proportional hazards analysis for progression-
free and overall survival
Progression-
free survival Overall survival
HR (95%CI) P HR (95%CI) P
Treatment arm
No
lymphadenectomy
a
0.16 0.56
Lymphadenectomy 0.72 (0.46–1.14) 0.85 (0.49–1.47)
Grade
1o r2
a 0.01 0.08
3 1.84 (1.14–2.96) 1.66 (0.93–2.95)
HR¼hazard ratio CI¼confidence interval.
aReference category
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(Baiocchi et al, 1998). Univariate analysis revealed that the
presence of metastatic nodes correlated with survival (HR¼4.61)
in the control group. Conversely, in the lymphadenectomy group,
nodal involvement was no longer a prognosticator for survival
suggesting that the removal of all nodes increased the likelihood of
complete tumour debulking. Bendetti Panici et al (2005) showed
that in patients with advanced ovarian cancer undergoing
systematic lymphadenectomy node positivity was still correlated
with survival as although systematic lymphadenectomy did not
contribute to optimal tumour debulking and therefore to clinical
outcome.
Standard of postoperative care for patients with FIGO stage IIb
to IV ovarian cancer is adjuvant chemotherapy. On the contrary,
before the publication of ICON1-Action studies (International,
2003) there was no compelling evidence to support early
institution of cytotoxic chemotherapy in stage I to IIa disease.
Therefore, in such cases, the use of postoperative chemotherapy
was left at the discretion of the treating physician who tried to
identify a subgroup of patients at high risk for relapse depending
on features that are predictive of inferior survival like incomplete
staging and higher stage or tumour grading. Nowadays the
majority of patients with early stage ovarian cancer will require
adjuvant platinum-based with or without taxanes chemotherapy.
As a significant proportion of patients undergoing systemic
lymphadenectomy were upstaged to stage IIIc that warrants the
institution of postoperative chemotherapy we would have expected
more patients treated with chemotherapy in the lymphadenectomy
arm than in the control arm. On the contrary, due to the lack of
evidence based guidelines, it seemed that clinicians preferred to err
on the side of overtreatment in node negative patients who entered
the control arm. Thus, the control arm was associated with a trend
toward higher use of postoperative chemotherapy. In particular,
there were seven patients out postoperative chemotherapy in the
control arm. The Action trial (Trimbos et al, 2003) suggested that the
patients with early-stage ovarian cancer after optimal surgical
staging (and nodal sampling was still considered an adequate
approach to retroperitoneum) showed neither an overall survival
nor a relapse free survival benefit from adjuvant chemotherapy. Our
study showed that 22% of apparent early-stage ovarian cancer
harbour more advanced disease and indirectly reinforce a con-
servative approach aimed at sparing low-risk patients with negative
nodes (after lymphadenectomy) unnecessary cytotoxic treatments.
There were no clear differences in the pattern of relapses and,
specifically, there was a similar number of retroperitoneal relapses
between the two arms.
This study was underpowered to detect a limited but still
clinically important effect of systematic lymphadenectomy on
progression-free or overall survival. Although nonstatistically
significant, the punctual estimates of the HRs for progression or
death from any cause favored lymphadenctomy and this finding is
even more interesting considering that less patients received
postoperative chemotherapy in the lymphadenectomy arm than in
the control arm. In conclusion, systematic lymphadenectomy
seems a relatively safe and acceptable surgical procedure when
performed in selected gynecologic oncology institutions and it
guarantees the optimal accuracy of staging which in turn allows to
tailor postoperative treatments.
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